Talvey: wysoka skuteczność, głęboka i trwała odpowiedź^1,2#

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.

Manage cookie settings

Talkwetamab – nowa nadzieja dla pacjentów ze szpiczakiem plazmocytowym

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.

Manage cookie settings

Czy każdy pacjent będzie leczony zarówno Tecvayli jak i Talvey?

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.

Manage cookie settings

U kogo zastosować Talvey w pierwszej / drugiej kolejności?

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.

Manage cookie settings

Czy TALVEY może być stosowany zarówno przed jak i po terapiach anty-BCMA?

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.

Manage cookie settings

Jakie są kluczowe cechy wyróżniające TALVEY na tle innych terapii dwuswoistych?

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.

Manage cookie settings

Profilaktyka AEs charakterystycznych dla GPRC5D – co warto wiedzieć?

^#mediana obserwacji wynosząca do 30 miesięcy*

ChPL Talvey^®, czerwiec 2024
EHA Library. Rasche L. 06/13/2024; 420979; P915